Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gesham Magombedze

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Antimicrobial Agents and Chemotherapy|August 16, 2017
Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease RecurrenceJotam G Pasipanodya, Deborah Ogbonna, Beatriz E Ferro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to OrangesGesham Magombedze, Jotam G Pasipanodya, Shashikant Srivastava, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary TuberculosisJotam G Pasipanodya, Wynand Smythe, Corinne S Merle, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2017
Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for TuberculosisShashikant Srivastava, Gesham Magombedze, Thearith Koeuth, et al.
The Journal of Antimicrobial Chemotherapy|March 2, 2019
Once-a-week tigecycline for the treatment of drug-resistant TBDevyani Deshpande, Gesham Magombedze, Shashikant Srivastava, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2021
Nouveau short-course therapy and morphism mapping for clinical pulmonary <i>Mycobacterium kansasii</i>Shashikant Srivastava, Jann-Yuan Wang, Gesham Magombedze, et al.
Science Advances|September 7, 2017
Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosisDevyani Deshpande, Shashikant Srivastava, Moti Chapagain, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematicsShashikant Srivastava, Devyani Deshpande, Gesham Magombedze, et al.
Scientific Reports|December 9, 2022
Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycleIlean Chai, Dmytro Kornyeyev, Edward Hsieh, et al.
The Journal of Infectious Diseases|November 8, 2024
Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment InterruptionGesham Magombedze, Elena Vendrame, Devi SenGupta, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|August 16, 2017
Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease RecurrenceJotam G Pasipanodya, Deborah Ogbonna, Beatriz E Ferro, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to OrangesGesham Magombedze, Jotam G Pasipanodya, Shashikant Srivastava, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 30, 2018
Artificial intelligence-derived 3-Way Concentration-dependent Antagonism of Gatifloxacin, Pyrazinamide, and Rifampicin During Treatment of Pulmonary TuberculosisJotam G Pasipanodya, Wynand Smythe, Corinne S Merle, et al.
Antimicrobial Agents and Chemotherapy|June 7, 2017
Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for TuberculosisShashikant Srivastava, Gesham Magombedze, Thearith Koeuth, et al.
The Journal of Antimicrobial Chemotherapy|March 2, 2019
Once-a-week tigecycline for the treatment of drug-resistant TBDevyani Deshpande, Gesham Magombedze, Shashikant Srivastava, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2021
Nouveau short-course therapy and morphism mapping for clinical pulmonary <i>Mycobacterium kansasii</i>Shashikant Srivastava, Jann-Yuan Wang, Gesham Magombedze, et al.
Science Advances|September 7, 2017
Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosisDevyani Deshpande, Shashikant Srivastava, Moti Chapagain, et al.
The Journal of Antimicrobial Chemotherapy|November 13, 2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematicsShashikant Srivastava, Devyani Deshpande, Gesham Magombedze, et al.
Scientific Reports|December 9, 2022
Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycleIlean Chai, Dmytro Kornyeyev, Edward Hsieh, et al.
The Journal of Infectious Diseases|November 8, 2024
Early Viral Dynamics Predict Human Immunodeficiency Virus Posttreatment Control After Analytic Treatment InterruptionGesham Magombedze, Elena Vendrame, Devi SenGupta, et al.
Pageof 4